Poster Presentations Session I
Poster Presentations Session I Monday, 31 October 2016
POSTERS SET-UP: 8:30 - 8:45
POSTERS DISPLAY HOURS: 8:45 - 14:15
POSTER AUTHOR DISCUSSION: 13:15 - 14:15
POSTERS DISMANTLE: 14:15


Poster display locations are shown below the poster codes
RESEARCH ON METHODS - Clinical Outcomes Methods
PRM1
A1
COMPARISON OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (ESMO-MCSB) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) FRAMEWORK FOR ASSESSING VALUE IN CANCER CARE
Rémuzat C1, Chouaid C2, Auquier P3, Borget I4, Kornfeld A1, Toumi M5
1Creativ-Ceutical, Paris, France, 2INSERM U955 and Université Paris Est (UPEC), UMR U955, Faculté de médecine, Créteil, France, 3Aix-Marseille Université, Université de la Méditerranée, Marseille, France, 4Institut Gustave Roussy, Villejuif, France, 5Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PRM2
A2
CONSIDERATIONS IN META-ANALYTIC NETWORK DESIGN: THE CASE OF PLATINUM DOUBLET CHEMOTHERAPIES IN ADVANCED NON-SMALL CELL LUNG CANCER (ADVNSCLC)
Goring SM1, Scott DA2, Briggs A3, Penrod JR4, Wilson JB1, Waser N1, Thompson JC2, Korytowsky B4, Chirita O5, Wong B4, Yuan Y4
1ICON Epidemiology, Vancouver, BC, Canada, 2ICON Health Economics & Epidemiology, Abingdon, UK, 3University of Glasgow, Glasgow, UK, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5Bristol-Myers Squibb, Uxbridge, UK

PRM3
A3
CAUSES OF DEATH STATISTICS UNDERESTIMATE THE BURDEN OF HEAD AND NECK (H&N) CANCERS: A NATIONWIDE STUDY FROM FRANCE IN 2008-2012 (EPICORL STUDY)
Schwarzinger M1, Even C2, Pointreau Y3, Geoffrois L4, Bec M5, Godard C5, Huguet F6, Témam S2, Sagaon Teyssier L1, Levy-Bachelot L5
1THEN (Translational Health Economics Network), Paris, France, 2Institut Gustave Roussy, Villejuif, France, 3Centre Jean Bernard-Clinique Victor Hugo, LE MANS, France, 4Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France, 5MSD France, Courbevoie, France, 6Tenon hospital, Paris, France

PRM4
A4
A REVIEW EVALUATING THE VALIDITY OF MOTION-BASED GAMING PLATFORMS TO MEASURE CLINICAL OUTCOMES IN CLINICAL RESEARCH
Byrom B1, Breedon P2, Muehlhausen W3
1ICON Clinical Research, Marlow, UK, 2Nottingham Trent University, Nottingham, UK, 3ICON plc, Dublin 18, Ireland

PRM5
A5
MAN VERSUS MACHINE - IS ACCURATE AUTOMATION OF DATA ABSTRACTION ACHIEVABLE?
Kiff C1, Scott DA1, Thompson JC1, Quigley JM2, Eaton J1
1ICON Health Economics and Epidemiology, Abingdon, UK, 2ICON Health Economics & Epidemiology, Abingdon, UK

PRM6
A6
EVALUATING THE QUALITY OF EVIDENCE FROM THE ASPIRE AND ENDEAVOR CLINICAL TRIALS USING THE GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT AND EVALUATION (GRADE) APPROACH
Biedermann P1, Esposito B2, Glen C3, Pippo L2, Avallone G2, Gonzalez-McQuire S1, Gatta F1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen GmbH, Milan, Italy, 3Oxford PharmaGenesis Ltd, Tubney, UK

PRM7
A7
PSYCHOMETRIC ANALYSES OF CLINICAL OUTCOME ASSESSMENT (COA) QUESTIONNAIRES DESIGNED TO EVALUATE SATISFACTION WITH PHARMACOLOGICAL STRESS AGENTS (PSAS) USED IN ECHOCARDIOGRAPHY
Spalding J1, Hudgens S2, Litcher-Kelly L3, Shields A3, Kitt T1, Ojo O3, Kristy R1, Lee E1, Mathias A3, Morrissey L3, Houle C1
1Astellas Pharma Global Development, Northbrook, IL, USA, 2Clinical Outcomes Solutions, Tucson, AZ, USA, 3Adelphi Values, Boston, MA, USA

PRM8
A8
SINGLE-ARM TRIALS IN SYSTEMATIC REVIEWS: ARE THEY ADEQUATELY CAPTURED BY EXISTING SEARCH FILTERS?
O'Rourke JM1, Ward KE2, Thompson JC2
1ICON Health Economics & Epidemiology, Abingdon, UK, 2ICON Health Economics and Epidemiology, Abingdon, UK

PRM9
A9
GUIDELINES FOR TRANSLATION AND CROSS-CULTURAL ADAPTATION OF NON-TECHNICAL SKILLS RATING INSTRUMENTS
Repo JP1, Rosqvist E2
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Central Finland Health Care District, Jyväskylä, Finland, Jyvaskyla, Finland

PRM10
A10
EXPECTED IMPACT OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (ESMO-MCSB) ON HEALTH TECHNOLOGY ASSESSMENT
Rémuzat C1, Chouaid C2, Auquier P3, Borget I4, Kornfeld A1, Toumi M5
1Creativ-Ceutical, Paris, France, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Aix-Marseille Université, Université de la Méditerranée, Marseille, France, 4Institut Gustave Roussy, Villejuif, France, 5Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PRM11
A11
WEAKNESS OF REGISTRATION BIOEQUIVALENT DRUGS
Krakowian P, Iwanczuk T, Zaremba A, Misiak J, Tatara T, Wysoczanski W
Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland

PRM12
A12
APPLYING THE ACCEPTED TECHNIQUES OF INDIRECT TREATMENT COMPARISON TO MEET PAYER NEEDS FOR BRIVARACETAM VERSUS ADJUNCTIVE ANTIEPILEPTIC MEDICATIONS FOR THE TREATMENT OF FOCAL SEIZURES IN ADULT PATIENTS. DO THEY REFLECT THE NEED FOR INDIVIDUALISED PATIENT CARE IN HETEROGENEOUS POPULATIONS IN EPILEPSY?
Charokopou M1, Harvey R2, Srivastava K3, Townsend R4, Borghs S5
1UCB Pharma, Brussels, Belgium, 2BresMed Health Solutions, Sheffield, UK, 3BresMed Health Solutions, Goa, India, 4UCB Pharma, Smyrna, GA, USA, 5UCB Pharma, Slough, UK

PRM13
A13
ANALYSIS OF THE ASCO VALUE FRAMEWORK NET HEALTH BENEFIT SCORE AS A TOOL FOR ASSESSING NOVEL THERAPIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Cork D, Nelson L, Curry A
SIRIUS Market Access, London, UK

PRM14
A14
PATIENCE IS A VIRTUE WHEN CONNECTING EVIDENCE NETWORKS
Halfpenny NJ1, Quigley JM2, Gurung B3, Scott DA3, Thompson JC2
1ICON Health Economics, Abingdon, UK, 2ICON Health Economics & Epidemiology, Abingdon, UK, 3ICON Health Economics and Epidemiology, Abingdon, UK

PRM15
A15
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) NET HEALTH BENEFIT (NHB) ASSESSMENT TOOL: WHICH IMPLICATIONS FOR VALUE ASSESSMENT OF CANCER THERAPIES?
Rémuzat C1, Chouaid C2, Auquier P3, Borget I4, Kornfeld M1, Toumi M5
1Creativ-Ceutical, Paris, France, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Aix-Marseille Université, Université de la Méditerranée, Marseille, France, 4Institut Gustave Roussy, Villejuif, France, 5Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

PRM16
A16
A NEW MODEL TO IDENTIFY MULTIVARIATE CAUSES OF HIGH COST IN PATIENT WITH ADVANCED LIVER DISEASE
Turri JA1, Ferreira LA2
1Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil, 2University of Sao Paulo, Sao Paulo, Brazil

PRM17
A17
WITHDRAWN

PRM18
A18
PAYER REQUIREMENTS IN THE TREATMENT OF CHRONIC HEART FAILURE
Bergenheim K1, Hellsten Kronander A2, Lauks S3, van Engen A4
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, Gothenburg, Sweden, 3Quintiles, Reading, UK, 4Quintiles Advisory Services, Hoofddorp, The Netherlands

PRM19
A19
DEVELOPING A CLASSIFICATION SYSTEM OF PATIENTS BASED ON RISK RELATED TO EPIDEMIOLOGICAL AND DEMOGRAPHIC VARIABLES
Romero Prada ME1, Marrugo R2, Celis S3, Alfonso Quiñones PA2, Vivas-Consuelo D4
1Fundación Salutia, Bogotá, Colombia, 2Salutia Foundation, Bogotá, Colombia, 3Salutia Foundation, Bogota, Colombia, 4Universitat Politècnica de València (UPV), Valencia, Spain

PRM20
A20
OPTIMAL DESIGN OF PRE-AUTHORIZATION TRIALS FOR EFFECTIVENESS EVALUATION IN SEVERE ASTHMA
Karcher H1, Meng J2, Fu S2, Loefroth E3, Cao H4, Peress E5
1LASER Analytica, London, UK, 2LASER Analytica, Loerrach, Germany, 3Novartis Sverige AB, Stockholm, Sweden, 4Novartis, East Hanover, NJ, USA, 5Novartis, Basel, Switzerland

PRM21
A21
DETECTION AND ANALYSIS OF THERAPY LINES AND OTHER EVENT SEQUENCES IN CLAIMS DATA
Ertl J, Hapfelmeier J, Ansorge S
arvato health analytics, Munich, Germany

PRM22
A22
EVALUATING THE EFFECTIVENESS OF TREATMENTS OF OPIOID USE DISORDER BASED ON RECOVERY OUTCOMES: HOW TO BRIDGE THE DISCONNECT BETWEEN CLINICAL TRIAL OUTCOMES AND RECOVERY OUTCOMES?
Elroy PW1, Ronquest NA2, Barnes A3, Nadipelli VR2, Akehurst R3
1BresMed Health Solutions, Utrecht, The Netherlands, 2Indivior Inc., Richmond, VA, USA, 3BresMed Health Solutions, Sheffield, UK

PRM23
A23
PARAMETRIC SIMULATION OF HEADACHE DAY FREQUENCY USING A NEGATIVE BINOMIAL DISTRIBUTION: A CASE STUDY OF ERENUMAB IN EPISODIC MIGRAINE
Porter JK1, Brennan A2, Palmer S3, Sapra S4, Cristino J1
1Amgen (Europe) GmbH, Zug, Switzerland, 2University of Sheffield, Sheffield, UK, 3University of York, Heslington, York, UK, 4Amgen Inc, Thousand Oaks, CA, USA

PRM24
A24
DIFFERENCES IN PERCEPTION OF HEALTH-RELATED QUALITY OF LIFE ASSOCIATES TO SOCIOECONOMIC, CULTURAL AND HOUSING FACTORS: MULTILEVEL ANALYSIS
Romero Prada ME1, Alvis Guzman N2, Sanabria M3, Celis S4, Lancheros J5, Gallo D5, Huerfano LM5
1Universidad Nacional de Colombia, Bogota, Colombia, 2Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Salutia´s Foundation- Research center in economy, management and health technologies., Bogota, Colombia, 4Salutia Foundation, Bogota, Colombia, 5Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia

PRM25
A25
INCREASING THE INTERPRETABILITY OF PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FINDINGS USING A MIXED METHODS DESIGN: AN EXAMPLE IN A RARE CARDIAC CLINICAL TRIAL
Marrel A, Fofana F, Guillemin I
Mapi Group - Patient-Centered Outcomes, Lyon, France

PRM26
A26
SYNTHESIS OF BINARY OUTCOME DATA ON THE LOG-ODDS AND ABSOLUTE RISK SCALES – A CASE STUDY IN CHRONIC HEPATITIS C
Nagy L1, Kay G1, Parker C1, Padhiar A1, O'Rourke JM1, Quigley JM1, Mealing S1, Hawkins N2
1ICON Health Economics & Epidemiology, Abingdon, UK, 2University of Glasgow, Glasgow, UK

PRM27
A27
FOUR DECADES OF RASCH ANALYSIS ON PATIENT-REPORTED OUTCOMES INSTRUMENTS VALIDATION: A SYSTEMATIC LITERATURE REVIEW
de Bock E, Williams P, Tugaut B, Guillemin I
Mapi Group, Patient-Centered Outcomes, Lyon, France

PRM28
A28
REVIEW OF METHODS FOR COMBINING INDIVIDUAL AND AGGREGATE DATA IN A META-ANALYSIS
Kapso Kapnang R1, Thokagevistk K2, Vataire A2, Aballéa S2
1National School For Statistics and Information Analysis (ENSAI), Bruz, France, 2Creativ-Ceutical, Paris, France

PRM29
A29
EPIDEMIOLOGICAL PROFILE OF KNEE ARTHROPLASTY SURGERY IN HEALTH CARE SYSTEM OF PUBLIC EMPLOYEES LOCATED IN NORTHEAST BRAZIL BETWEEN JULY 2014 AND DECEMBER 2015
Silva Jd1, de Souza NN2, Silva Sd1, Novis CS1
1Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, 2UFBA, SALVADOR, Brazil

PRM30
A30
EVALUATION OF THE EFFECT OF PHARMACEUTICAL CARE INTERVENTIONS ON THE MEAN DAILY DOSE OF ORAL ANTIDIABETES DRUGS IN A NIGERIAN TERTIARY HOSPITAL
Ogbonna B
NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria

RESEARCH ON METHODS - Cost Methods
PRM31
A31
ECONOMIC AND HUMANISTIC IMPACT ASSUMPTIONS FOR HYPOGLYCEMIC EVENTS: IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSES IN INSULIN-TREATED DIABETES
Tunis SL1, Klinkenbijl B2, Graham C3, Weaver D3
1Independent, Indianapolis, IN, USA, 2Dexcom, Inc., Essertines sur Rolle, Switzerland, 3Dexcom, Inc., San Diego, CA, USA

PRM32
A32
VALIDATING THE PROJECTED MORTALITY RATES USED IN ONCOLOGY COST-EFFECTIVENESS ANALYSIS: A PITFALL OF SIMPLE BENCHMARKING WITH LIFE TABLE AGE-SPECIFIC MORTALITY RATES FOR A TRIAL POPULATION
Zhang Y1, Dyer M2, Vereecken W2
1Astrazeneca, Gaithersburg, MD, USA, 2AstraZeneca UK Ltd., Luton, UK

PRM33
A33
HEALTH ECONOMIC COSTING METHODS AND REPORTING IN AUSTRIA
Mayer S, Kiss N, Laszewska A, Simon J
Medical University of Vienna, Vienna, Austria

PRM34
A34
WHICH COSTS MATTER? COSTS INCLUDED IN ECONOMIC EVALUATION AND THEIR IMPACT ON DECISION UNCERTAINTY: THE EXAMPLE OF ACUTE MYOCARDIAL INFARCTION
Lomas JR1, Asaria M2, Bojke L1, Richardson G3, Walker S2
1University of York, York, UK, 2University of York, Heslington, York, UK, 3University of York, Heslington, UK

PRM35
A35
COMPARING DIFFERENT DATA ON DISEASE BURDEN IN MULTIPLE SCLEROSIS
Berg J1, Gannedahl M1, Capsa D1, Eriksson J2, Kobelt G3
1Mapi, Stockholm, Sweden, 2Mapi Group, Stockholm, Sweden, 3European Health Economics, Mulhouse, France

PRM36
A36
VALUING CANCER-RELATED PREMATURE MORTALITY: A COMPARISON OF CONSUMER-LED VERSUS PRODUCER-LED APPROACHES
Hanly P
National College of Ireland, Dublin, Ireland

PRM37
A37
WITHDRAWN

PRM38
A38
A SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH-ECONOMIC EVALUATIONS OF TREATMENTS FOR RARE DISEASES
Garcia Sanchez JJ, Norman DL
MAP BioPharma Limited, Cambridge, UK

PRM39
B1
EVALUATING THERAPEUTIC TREATMENTS FOR PSORIATIC ARTHRITIS: CAN WE MAKE BETTER USE OF PATIENT DATA REGISTRIES?
Walton MJ1, Bojke L1, Manca A2, Patton T1
1University of York, York, UK, 2University of York, Heslington, York, UK

PRM40
B2
CHALLENGES IN ECONOMIC EVALUATIONS CONDUCTED ALONGSIDE CLINICAL TRIALS OF SCHIZOPHRENIA: THE CASE OF THE ACTIONS STUDY
Kiss N, Simon J
Medical University of Vienna, Vienna, Austria

PRM41
B3
VALUING INFORMAL CARE: MAKING NORMATIVE JUDGMENTS IN A POSITIVE MILIEU
Hanly P1, Maguire R1, Balfe M2, Sharp L3
1National College of Ireland, Dublin, Ireland, 2University College Cork, Cork, Ireland, 3Newcastle University, Newcastle, UK

PRM42
B4
SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSIS ON VACCINES
Itria A1, Loze P2
1GOIAS UNIVERSITY, goiânia, Brazil, 2Goiania University, GOIANIA , GOIÁS, Brazil

PRM43
B5
THREE METHODS FOR MEASURING PRODUCTIVITY LOSSES DUE TO HEALTH RELATED PRESENTEEISM IN ECONOMIC EVALUATIONS
Shephard C, Hirst A, Buckland A, Vlachaki I
WG Access Ltd, London, UK

PRM44
B6
A GENERAL MODEL FOR THE ESTIMATION OF SOCIETAL COSTS OF LOST PRODUCTION AND INFORMAL CARE IN ITALY
Pradelli L, Ghetti G
AdRes Srl, Torino, Italy

PRM45
B7
HOW TIME AND SEVERITY INCREASES THE OVERALL COST AND RESOURCE UTILIZATION OF PATIENT WITH SEVERE LIVER DISEASE. MAIN BURDENS AND CONSEQUENCES TO HEALTH SYSTEM
Turri JA, Ferreira LA
Sao Paulo Medical School - Sao Paulo University, Sao Paulo, Brazil

PRM46
B8
THE ECONOMIC BURDEN OF PULMONARY EMBOLISM IN EUROPE
Gumbs PD1, Ling-Hsiang Chuang L2, Cohen AT3, Agnelli G4, Willich SN5, Monreal M6, Jimenez D7, van Hout B8
1Daiichi-Sankyo Europe GmbH, Munich, Germany, 2Pharmerit, Rotterdam, The Netherlands, 3Guy's and St Thomas' NHS Foundation Trust, London, UK, 4University of Perugia, Italy, Perugia, Italy, 5Charité - Universitätsmedizin Berlin, Berlin, Germany, 6Hospital Universitari Germans Trias I Pujol, Barcelona, Spain, 7Ramon y Cajal Hospital, IRYCIS and Alcala University, Madrid, Spain, 8Pharmerit International, York, UK

PRM47
B9
COST-EFFECTIVENESS OF BRIVARACETAM VERSUS OTHER ANTIEPILEPTIC DRUGS USED AS ADJUNCTIVE TREATMENT FOR FOCAL SEIZURES IN THE UK: A DISCRETE EVENT SIMULATION MODEL
Charokopou M1, Sander J2, Saha R3, Beard S4, Kidd R4, Coward E5, Plumb J1
1UCB Pharma, Brussels, Belgium, 2UCL Institute of Neurology, London, UK, 33. Nuffield Health Hospital, Brighton, UK, 4BresMed Health Solutions, Sheffield, UK, 5UCB Pharma, Slough, UK

PRM48
B10
THE VALUE OF TIMELY IMPLEMENTATION IN HIV/STI TESTING: COST-EFFECTIVENESS VS. SPEED OF INTERVENTION ROLLOUT
Beck E1, Armbruster B2, Birkett M3, Mustanski B3
1Creativ-Ceutical, London, UK, 2Northwestern University, Evanston, IL, USA, 3Northwestern University, Chicago, IL, USA

PRM49
B11
THE COST-EFFECTIVENESS OF BLUE-LIGHT THERAPY VS FIXED COMBINATION OF CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE GEL IN THE TREATMENT OF MILD-TO-MODERATE PSORIASIS
Ansaripour A1, Thio HB2, Maessen R3, Redekop WK1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, 3Philips Lighting, Eindhoven, The Netherlands

PRM50
B12
CHALLENGING MODEL COMPLEXITY; A SIMPLER APPROACH FOR DEVELOPING MARKETS
Marijam A, Standaert B
GSK Vaccines, Wavre, Belgium

PRM51
B13
THE BENEFITS OF A HOLISTIC VIEW: CONSIDERING MULTIPLE HEALTH OUTCOMES FOR HIV AND STI TESTING
Beck E1, Armbruster B2, Birkett M3, Mustanski B3
1Creativ-Ceutical, London, UK, 2Northwestern University, Evanston, IL, USA, 3Northwestern University, Chicago, IL, USA

PRM52
B14
CONCEPTUAL MODELLING FOR COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL THERAPY WITH RANIBIZUMAB, AFLIBERCEPT OR BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION
Goodall M, Tosh J, Alshreef A, Tappenden P
University of Sheffield, Sheffield, UK

PRM53
B15
CHALLENGES IN THE HEALTH ECONOMICS OF ACUTE PAIN: A RAPID REVIEW OF THE LITERATURE
Braileanu G1, Johnson BC1, Ashraf S1, Borrill J1, Hirst M2
1Adelphi Values, Bollington, Cheshire, UK, 2Mundipharma International Ltd, Cambridge, UK

PRM54
B16
WITHDRAWN

RESEARCH ON METHODS - Databases & Management Methods
PRM55
B17
IDENTIFYING POTENTIAL EARLY BIOMARKERS OF ACUTE MYOCARDIAL INFARCTION IN THE BIOMEDICAL LITERATURE: A COMPARISON OF TEXT MINING AND MANUAL SIFTING TECHNIQUES
Paisley S, Seva J, Stevenson M, Archer R, Preston L, Chilcott J, Thornhill M
University of Sheffield, Sheffield, UK

PRM56
B18
VIABILITY OF USING ELECTRONIC MEDICAL RECORDS FROM EUROPEAN COUNTRIES AS DATA IN NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINAL STUDY OF PATIENTS WITH ASTHMA AND/OR COPD)
Wang X1, Sveréus A2, Rennard S3, Hiller J4, Wong D4, Nasuti P4, Jenner H4, McKenney A4, Gerhardsson de Verdier M2
1AstraZeneca, Gaithersburg, MD, USA, 2AstraZeneca, Gothenburg, Sweden, 3AstraZeneca, Melbourn, UK, 4IMS Health, London, UK

PRM57
B19
LINKAGE OF THE PHARMO DATABASE NETWORK AND THE NETHERLANDS PERINATAL REGISTRY TO CONSTRUCT A COHORT THAT CAPTURES PREGNANCY AND POSTNATAL OUTCOMES
Houben E, Bezemer ID, Herings RM
PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PRM58
B20
ACCURACY OF TEXT PROCESSING TOKENISERS FOR AUTOMATED IDENTIFICATION OF DISEASES AND INTERVENTIONS IN ABSTRACTS OF STUDIES ON HUMANISTIC AND ECONOMIC BURDEN OF DISEASE
Challen R1, Martin A2, Martin C2
1Terminological Ltd, Hove, UK, 2Crystallise Ltd., London, UK

PRM59
B21
ELICITING PAYERS PREFERENCES IN CENTRAL AND EASTERN EUROPE: RESULTS OF MCDA CASE STUDY
Piniazhko O1, Zalis'ka O1, Zah V2
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Health Economist, Belgrade, Serbia

PRM60
B22
COMPARISON OF ESTIMATED EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS (RA) IN LARGE INSURANCE DATABASES USING A CLAIMS-BASED ALGORITHM
Rascati KL, Popp R, Davis M
The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PRM61
B23
ETHICAL STANDARDS IN REPORTING RESEARCH FROM RETROSPECTIVE OBSERVATIONAL STUDIES BASED ON DATABASES USING ANONYMOUS AND PERSONALLY UNIDENTIFIABLE
Hiroi S1, Uda A1, Tokaji A2, Takeshima T3, Iwasaki K3, Mishiro I1
1Takeda Pharmaceutical Company Ltd., Tokyo, Japan, 2MDS-CMG Inc., Tokyo, Japan, 3Milliman, Tokyo, Japan

PRM62
B24
USE OF SURVEILLANCE DATABASES TO DESCRIBE INFLUENZA EPIDEMIOLOGY IN EUROPE
Riera M, Ferreira G, Cattaert T, Verstraeten T
P95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium

PRM63
B25
PEDIATRIC REGISTRY OF PATIENTS WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA RECEIVING OMALIZUMAB
Namazova-Baranova L, Vishneva E, Dobrynina E, Alekseeva A, Levina J, Efendieva K, Smirnov V, Antonova E, Voznesenskaya N, Selimzianova L
Scientific Centre of Children Health, Moscow, Russia

PRM64
B26
ARTIFICIAL INTEGLIGENCE TO SUPPORT THE DEVELOPMENT OF HEALTH TECHNOLOGY ASSESSMENT REPORTS
Sekiewicz B, Rodak W, Rutkowski J, Plisko R, Miazga P
HTA Consulting, Krakow, Poland

PRM65
B27
THE USE OF ADMINISTRATIVE DATA TO DETERMINE PREVALENCE AND INCIDENCE OF COPD: A SYSTEMATIC REVIEW
Gothe H1, Rajsic S2, Gottfried E3, Vukicevic D4, Siebert U5
1Medical Faculty, TU Dresden / UMIT, Dresden / Hall in Tirol, Germany, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Hall in Tirol, Austria, 3Main Association of the Austrian Social Insurance Institutions, Vienna, Austria, 4UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, 5and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

PRM66
B28
PROQOLID DATABASE: EVOLUTION OF CONTENT, STRUCTURE, AND FUNCTIONALITIES (2012-2016) - INTEGRATION IN EPROVIDE, A NEW ONLINE PLATFORM DEDICATED TO CLINICAL OUTCOME ASSESSMENT (COA) RESEARCH
Perret C, Perrier L, Castex M, Acquadro C
Mapi Research Trust, Lyon, France

PRM67
B29
MEASURES TAKEN BY THE ROMANIAN MINISTRY OF HEALTH FOR BETTER ACCESS TO ANTI-EGFR DRUGS
Turcu-Stiolica A, Subtirelu M, Mic OC
University of Medicine and Pharmacy, Craiova, Romania

PRM68
B30
MARKOV MODELS FOR HEALTH ECONOMIC EVALUATION MODELLING IN R WITH THE HEEMOD PACKAGE
Filipovic-Pierucci A, Zarca K, Durand-Zaleski I
APHP, Paris, France

PRM69
B31
DEVELOPMENT OF A SEARCH ENGINE FOR THE MEDLINE DATABASE WITH SEARCH RESULTS RANKING FROM THE PERSPECTIVE OF EVIDENCE-BASED MEDICINE
Kolbin A1, Kamalov M2, Dobrynin V2, Balykina Y2, Verbitskaya E1
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Saint Petersburg State University, Saint Petersburg, Russia

PRM70
B32
AN INVESTIGATION INTO OPEN-SOURCE MODELLING IN HEALTH ECONOMICS: OPPORTUNITIES AND CHALLENGES
Mason N1, Kenworthy JJ2, Akehurst R3, Sullivan W1, Dunlop W2
1BresMed, Sheffield, UK, 2Mundipharma International Ltd, Cambridge, UK, 3BresMed Health Solutions, Sheffield, UK

PRM71
B33
PREDICTION OF COSTS ASSOCIATED WITH THE HOSPITAL MANAGEMENT OF HIV PATIENTS IN FRANCE USING AN ADVANCED DATA MINING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE
Prodel M1, Amaz C2, Vainchtock A2, Finkielsztejn L3, Aubin C3
1HEVA, LYON, France, 2HEVA, Lyon, France, 3ViiV Healthcare France, Marly-le-Roi, France

PRM72
B34
EVALUATING SOCIO-DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN THE UNITED STATES DEPARTMENT OF DEFENSE POPULATION
Wang L1, Li L1, Pandya S1, Baser O2
1STATinMED Research, Plano, TX, USA, 2Columbia University and STATinMED Research, New York, NY, USA

PRM73
B35
MAPPING THE INVOLVEMENT OF EUNETHTA PARTICIPANTS IN EU RESEARCH PROJECTS
Kozák A, Hankó B, Lám J, Merész G
Semmelweis University, Budapest, Hungary

PRM74
B36
EXPERT ELICITATION: CAN VARIATION IN ELICITED DISTRIBUTIONS BE EXPLAINED BY EXPERT HETEROGENEITY?
Jankovic D
University of York, York, UK

PRM75
B37
NETWORK ANALYSIS APPROACH TO EXPLORE SPONSOR INVOLVEMENT IN CLINICAL TRIALS
Merész G, Kozák A, Hankó B, Szócska M
Semmelweis University, Budapest, Hungary

PRM76
B38
CHARACTERISTICS OF A PATIENT POPULATION RECRUITED USING SOCIAL MEDIA (FACEBOOK) COMPARED WITH NEWSPAPER ADVERTISING (DAILY MAIL)
Wade AG, Crawford GM, McLennan K
Patients Direct, Glasgow, UK

PRM77
C1
NOT ALL COCHRANE REVIEWS ARE GOOD QUALITY SYSTEMATIC REVIEWS
Deshpande S1, Misso K1, Westwood M1, Stirk L1, de Kock S1, Kleijnen J1, Clayton D1, Kleijnen J2
1Kleijnen Systematic Reviews Ltd., York, UK, 2Maastricht University, Maastricht, The Netherlands

PRM78
C2
QUINOLONES UTILIZATION IN TWO TERTIARY HOSPITALS IN NIGERIA; EXPLORING DRUG USE TOWARDS IMPROVED TREATMENT OUTCOMES
Ogbonna B
NNAMDI AZIKIWE UNIVERSITY, ANAMBRA STATE, Nigeria

RESEARCH ON METHODS - Modeling Methods
PRM79
C3
MISSING THE VALUE OF HERD IMMUNITY IN COST-EFFECTIVENESS ANALYSIS. A SYSTEMATIC REVIEW
Nymark L
aarhus university, aarhus v, Denmark

PRM80
C4
ANALYSIS OF THE RELATIONSHIP BETWEEN BLOOD PRESSURE IN HEALTH CHECKUP AND EFFECTIVENESS OF ANTIHYPERTENSIVES
Iwasaki K1, Nakamura Y1, Hiroi S2, Uda A2, Shimasaki Y2, Koizumi H1
1Milliman, Tokyo, Japan, 2Takeda Pharmaceutical Company Ltd., Tokyo, Japan

PRM81
C5
IMPLICATIONS OF INTRODUCING PATIENT HETEROGENEITY IN COST EFFECTIVENESS MODELING
Foos V1, McEwan P2, Lamotte M3
1IMS Health, Zaventem, Belgium, 2Health Economics and Outcomes Research Ltd, Cardiff, UK, 3IMS Health, Vilvoorde, Belgium

PRM82
C6
A SYSTEMATIC REVIEW ON THE EVIDENCE OF ADEQUATE DISCOUNT RATES FOR VACCINES IN GERMANY
Koerber F, Redeker M, Wieninger E, Welte R
GSK, München, Germany

PRM83
C7
EMPIRICAL ASSESSMENT OF THE IMPACT OF MODEL CHOICE (MARKOV STATE TRANSITION VERSUS PARTITIONED SURVIVAL) IN MODELLING SMALL-CELL LUNG CANCER
McEwan P1, Gordon J1, Ward T1, Penrod JR2, Yuan Y2
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA

PRM84
C8
COMPARISON OF MARKOV MODELS USED FOR THE ECONOMIC EVALUATION OF COLORECTAL CANCER SCREENING: A SYSTEMATIC REVIEW
Silva NS
University of Chile, Santiago, Chile

PRM85
C9
REPLACING INPUT PROBABILITY DISTRIBUTIONS WITH MEAN VALUES CAN BIAS SIMULATION OUTPUT: AN ILLUSTRATION USING THE CORE DIABETES MODEL
McEwan P1, Foos V2, Lamotte M3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2IMS Health, Zaventem, Belgium, 3IMS Health, Vilvoorde, Belgium

PRM86
C10
STRUCTURED REVIEW OF HEALTH ECONOMIC MODELS IN ASTHMA
Enstone A1, Price G1, Viejo I2, Dunlop W2
1Adelphi Values Ltd, Bollington, UK, 2Mundipharma International Limited, Cambridge, UK

PRM87
C11
THE IMPLICATIONS OF PARAMETER INDEPENDENCE IN PROBABILISTIC SENSITIVITY ANALYSIS
Taylor M
York Health Economics Consortium, Heslington, York, UK

PRM88
C12
WITHDRAWN

PRM89
C13
RECOMMENDATIONS FOR THE CALCULATION OF TRANSITION PROBABILITIES IN MARKOV COHORT MODELS: A TARGETED LITERATURE REVIEW
Olariu E1, Cadwell K1, Fox D1, Hancock E1, Trueman D1, Ratcliffe M1, Grieve R2, Chevrou-Severac H3
1PHMR Ltd, London, UK, 2London School of Hygiene and Tropical Medicine, London, UK, 3Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland

PRM90
C14
TO WHAT EXTENT DOES THE PUBLISHED ECONOMIC ANALYSES OF TREATMENTS FOR OPIOID USE DISORDER CAPTURE ITS CHRONIC, RELAPSING NATURE AND ITS IMPACT ON SOCIETY?
Cranmer H1, Ronquest NA2, Barnes A1, Nadipelli VR2, Akehurst R1
1BresMed Health Solutions, Sheffield, UK, 2Indivior Inc., Richmond, VA, USA

PRM91
C15
REVIEW OF HEALTH ECONOMIC MODELS FOR ANTIBIOTICS
Virhage M1, Polyzoi M1, Geale K1, Geale K2, Corcoran K1, Anell B3
1PAREXEL International, Stockholm, Sweden, 2Umeå University, Umeå, Sweden, 3Parexel International, Stockholm, Sweden

PRM92
C16
AUTOMATIC EXTRACTION AND CLASSIFICATION OF PATIENTS’ SMOKING STATUS FROM FREE TEXT USING NATURAL LANGUAGE PROCESSING
Caccamisi A1, Jörgensen L2, Dalianis H3, Rosenlund M2
1Karolinska Institute, Stockholm, Sweden, 2IMS Health, Stockholm, Sweden, 3Stockholm University, Stockholm, Sweden

PRM93
C17
POTENTIAL EFFICACY OF LOMITAPIDE, A MTP (MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN) INHIBITOR, ON SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH): RESULTS OF AN EVENT MODELLING ANALYSIS
Leipold R1, Raal F2, Ishak J1, Phillips H3, Jakouloff D4, Deanfield J5
1Evidera, Bethesda, MD, USA, 2University of the Witwatersrand, Johannesburg, South Africa, 3Aegerion Pharmaceuticals Ltd, Berkshire, UK, 4Aegerion Inc, Cambridge, MA, USA, 5University College London, London, UK

PRM94
C18
THE IMPACT OF THE DIFFERENCE IN NATURAL HISTORY MODELS ON THE COST-EFFECTIVENESS OF ANTIVIRAL AGENTS FOR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C
Ishida H1, Ikai H2, Suenaga R1, Suka M3, Hirao T4
1Yamaguchi University, Ube, Japan, 2Yamaguchi University Hospital, Ube, Japan, 3The Jikei University School of Medicine, Tokyo, Japan, 4Kagawa University, MIki-Cho, Japan

PRM95
C19
DETERMINISTIC VS MICROSIMULATION; A CASE STUDY IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
van Oostrum I1, Guenther O2, Postma MJ3, Heeg BM4
1University Medical Center Groningen (UMCG), Groningen, The Netherlands, 2Merck KGaA, Darmstadt, Germany, 3University of Groningen, Groningen, The Netherlands, 4Ingress-health Netherlands, Rotterdam, The Netherlands

PRM96
C20
USE OF THE PERT AND UNIFORM DISTRIBUTIONS WITH THE CENTRAL LIMIT THEOREM (CLT) TO DECREASE VARIANCE IN COMPLICATION COST ESTIMATION IN PROBABILISTIC MODELS
Reynecke DP, Robson JP
FPH Care, Auckland, New Zealand

PRM97
C21
ACCOUNTING FOR THE IMPERFECT EXTERNAL VALIDITY OF DISCRETE CHOICE EXPERIMENTS WHEN PREDICTING DEMAND
Quaife M1, Terris-Prestholt F1, Di Tanna GL2, Vickerman P3
1London School of Hygiene and Tropical Medicine, London, UK, 2Queen Mary University of London, London, UK, 3University of Bristol, Bristol, UK

PRM98
C22
EXTRAPOLATION WITH PATIENT LEVEL TIME-TO-EVENT DATA IN VARIOUS DISEASE AREAS: A REVIEW OF CURRENT RECOMMENDATIONS AND GAPS
Kamra S, Kaur J, Kartheek J, Sehgal M, Siddiqui MK
PAREXEL International, Chandigarh, India

PRM99
C23
SAMPLING OF COMMONLY USED POPULATION CHARACTERISTICS: IS A NORMAL APPROXIMATION VALID?
Davis JA, Mittard V, Saunders R
Coreva Scientific, Freiburg im Breisgau, Germany

PRM100
C24
SYSTEMATIC REVIEW OF COST-EFFECTIVENESS MODELS IN DIABETES FOR INSULIN ANALOGUES
Ng CH1, Shafie AA2, Chaiyakunapruk N3, Tan YP1
1Universiti sains malaysia, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3Monash University Malaysia, Selangor, Malaysia

PRM101
C25
COST-EFFECTIVENESS DEPENDS ON THE SUBSEQUENT TREATMENT SEQUENCE: AN EXAMPLE FROM MULTIPLE SCLEROSIS
Asseburg C, Svensson J, Andersson E, Persson U, Willis M
The Swedish Institute for Health Economics (IHE), Lund, Sweden

PRM102
C26
EVALUATION OF METHODOLOGICAL VARIATIONS IN THE EVENT SIMULATION APPROACHES OF PUBLISHED HEALTH ECONOMIC MODELS IN OBESITY PREVENTION AND THERAPY
Schwander B1, Nuijten M2, Hiligsmann M3, Evers SM3
1AHEAD GmbH, Loerrach, Germany, 2Ars Accessus Medica, Jisp, The Netherlands, 3Maastricht University, Maastricht, The Netherlands

PRM103
C27
IDENTIFYING THE KEY PARAMETERS OF THE EUROPEAN-STUDY ON QUANTIFYING UTILITY OF INVESTMENT IN PROTECTION FROM TOBACCO (EQUIPT) MODEL
Nemeth B1, Kulchaitanaroaj P2, Lester-George A3, Huic M4, Pokhrel S2, Coyle D5, Coyle K2, Kaló Z6, Józwiak-Hagymásy J1, Nagy B1
1Syreon Research Institute, Budapest, Hungary, 2Brunel University, Uxbridge, Middlesex, UK, 3LeLan Solutions, Bristol, UK, 4Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia, 5University of Ottawa Faculty of Medicine, Ottawa, ON, Canada, 6Eötvös Loránd University (ELTE), Budapest, Hungary

PRM104
C28
HOW TO HANDLE DATA QUALITY ISSUES IN EQ-5D-5L VALUATION STUDIES. THE SPANISH CASE
Ramos-Goñi JM1, Craig BM2, Oppe M3, Ramallo-Fariña Y4, Pinto-Prades JL5, Luo N6, Rivero-Arias O7
1EuroQol Research Foundation, Tacoronte, Spain, 2University of South Florida, Tampa, FL, USA, 3EuroQol Research Foundation, Rotterdam, The Netherlands, 4HTA Unit of Canary Island Health Service, Canary Islands, Spain, 5University of Navarra, Plamplona, Spain, 6National University of Singpaore, Singapore, Singapore, 7University of Oxford, Oxford, UK

PRM105
C29
DIVERSITY IN ECONOMIC EVALUATIONS HAMPERS VALID DECISION-MAKING IN METASTATIC COLORECTAL CANCER
Merkens GL1, Tamminga HJ1, Hovels A2, Frederix GW1
1Utrecht University, Utrecht, The Netherlands, 2Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands

PRM106
C30
HOW ARE ADVERSE EFFECTS INCORPORATED IN COST-EFFECTIVENESS MODELS? A STUDY OF CURRENT PRACTICE IN ONCOLOGY STUDIES SUBMITTED TO HAS
Pibouleau L1, Drezet A1, Cognet M1, Scemama O1, Le galès C2
1Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France, 2INSERM, Villejuif Cedex, France

PRM107
C31
A NOVEL METHOD FOR EVALUATING VALUE ASSESSMENT FRAMEWORKS
Bentley TG1, Cohen JT2, Elkin EB3, Huynh J4, Mukherjea A5, Neville TH6, Mei MG7, Copher R8, Knoth RL8, Popescu I9, Zambrano JM1, Chang E1, Broder MS1, Lee J1
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, CA, USA, 3Memorial Sloan-Kettering Cancer Center, New York, CA, USA, 4Hematology Oncology Medical Group of San Fernando Valley, Encino, CA, USA, 5California State University, East Bay, Hayward, CA, USA, 6UCLA Department of Medicine, Los Angeles, CA, USA, 7City of Hope National Medical Center, Duarte, CA, USA, 8Eisai, Inc., Woodcliff Lake, NJ, USA, 9David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, CA, USA

PRM108
C32
MULTITHREADING: TURBOCHARGED COST-EFFECTIVENESS ANALYSES IN MICROSOFT EXCEL
Kiff C1, Mealing S2, Fenwick E1
1ICON Health Economics and Epidemiology, Abingdon, UK, 2ICON Health Economics & Epidemiology, Abingdon, UK

PRM109
C33
TREATMENT EFFICACY IN SEQUENCE MODELLING – A REVIEW OF PUBLISHED APPROACHES
Polyzoi M, Medin E
PAREXEL International, Stockholm, Sweden

PRM110
C34
A REVIEW ON THE CURRENT STATUS OF HEALTH ECONOMIC MODELING IN PERSONALIZED MEDICINE
Degeling K1, Koffijberg H2, IJzerman MJ2
1University of Twente, Enschede, The Netherlands, 2MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands

PRM111
C35
CURRENT ISSUES AND FUTURE RESEARCH PRIORITIES FOR HEALTH ECONOMIC MODELLING OF AT RISK POPULATION FOR ALZHEIMER’S DISEASE/DEMENTIA
Gustavsson A1, Green C2, Jones RW3, Simsek D4, de Reydet de Vulpillieres F5, Adlard N6, Bhattacharyya S7, Wimo A8, Förstl H9, Luthman S1
1Quantify Research, Stockholm, Sweden, 2Exeter University, Exeter, UK, 3The Research Institute for the Care of Older People, Bath, UK, 4Novartis Pharma AG, Basel, Switzerland, 5NOVARTIS PHARMA AG, Basel, Switzerland, 6Novartis Pharmaceuticals UK Ltd, Camberley, UK, 7Novartis Healthcare Pvt. Ltd., Hyderabad, India, 8Karolinska Institutet, Stockholm, Sweden, 9Technische Universität München, München, Germany

PRM112
C36
HYPERBOLIC DISCOUNTING OF EFFECTS IN ECONOMIC EVALUATIONS
Fókás L
Numerus, Tübingen, Germany

PRM113
C37
THE APPLICATION OF POPULATION MODELS TO IMPROVE ACCESS TO MEDICAL INNOVATIONS AND POPULATION HEALTH – A SYSTEMATIC REVIEW
Jahn B1, Conrads-Frank A2, Sroczynski G2, Rochau U3, Zauner G4, Bundo M2, Gyimesi M5, Endel G6, Popper N4, Siebert U7
1Department of Public Health, Health Services Research and Health Technology Assessment, Medical Informatics and Technology (UMIT), Hall i.T., Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Center for Personalized Medicine, Hall i.T./ Innsbruck, Austria, 4dwh GmbH, Vienna, Austria, 5Austrian Public Health Institute, Vienna, Austria, 6Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 7and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

PRM114
C38
REQUIREMENTS FOR ECONOMIC EVIDENCE ACROSS DIFFERENT HTA BODIES
Vlachaki I, Shephard C, Hirst A
WG Access Ltd, London, UK

PRM115
D1
THREE-MONTHLY LONG-ACTING FORMULATION OF PALIPERIDONE PALMITATE IS A DOMINANT TREATMENT OPTION, COST SAVING WHILE ADDING QALYS, COMPARED TO THE ONE-MONTHLY FORMULATION IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE
Arteaga Duarte C1, Colin X2, De Moor R1, Guillon P3, van Gils CW1
1IMS Health, Zaventem, Belgium, 2IMS Health, La Défense, France, 3Janssen-Cilag France, Issy-les-Moulineaux, Cedex, France

PRM116
D2
ESTIMATING THE APPROPRIATE PRICE DISCOUNTS FOR BIOSIMILARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN THE NORDIC SETTING USING AN EXCEL-BASED INTERACTIVE TOOL
Mahon R1, Cassel T2, Balkin PE1, Burke C1, Bhattacharyya S3, Gokhale SB4, Handin J2, Mendoza C5
1Product Lifecycle Services - Novartis Business Services, Dublin, Ireland, 2Sandoz A/S, Copenhagen, Denmark, 3Novartis Healthcare Pvt. Ltd., Hyderabad, India, 4Product Lifecycle Services - Novartis Business Services, Hyderabad, India, 5Sandoz International GmbH, Holzkirchen, Germany

PRM117
D3
ADAPTIVE PREDICTION OF SYMPTOMS RETURN UPON DISCONTINUATION OF OMALIZUMAB TREATMENT IN CHRONIC SPONTANEOUS URTICARIA PATIENTS
Saldana Miranda D1, Ferrer M2, Janssens N1, Gimenez-Arnau A3, Balp M1, Khalil S1, Risson V1
1Novartis Pharma AG, Basel, Switzerland, 2Clínica Universitaria de Navarra, Pamplona, Spain, 3Hospital del Mar. Parc de Salut Mar, Barcelona, Spain

PRM118
D4
MATHEMATICAL MODEL TO SYNTHESIZE NATURAL HISTORY OF TICK BORNE ENCEPHALITIS AND LYME BORRELIOSIS FOR THE PURPOSE OF COST-EFFECTIVENESS ANALYSIS
Mihajlovic J1, Hovius JW2, Sprong H3, Strle F4, Bogovic P4, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2The Academic Medical Center Amsterdam, Amsterdam, The Netherlands, 3National Institute for Public Health and the Environment (RIVM), Bithoven, The Netherlands, 4University Medical Center Ljubljana, Ljubljana, Slovenia

PRM119
D5
AN EXPLORATION OF TECHNIQUES FOR ADDRESSING UNCERTAINTY IN SURVIVAL ESTIMATES USED WITHIN PARTITIONED-SURVIVAL MODELS
Bullement A, Critchlow S
BresMed Health Solutions, Sheffield, UK

PRM120
D6
DO HEALTH TECHNOLOGY AGENCIES ACCEPT METHODS FOR DEALING WITH TREATMENT SWITCHING AND IMMATURE OS DATA?
Zhang Y1, Wright J2, Luke S3, Ryan J4, van Engen A5
1Astrazeneca, Gaithersburg, MD, USA, 2Quintiles, Reading, UK, 3AstraZeneca, Macclesfield, UK, 4AstraZeneca, Cambridge, UK, 5Quintiles Advisory Services, Hoofddorp, The Netherlands

PRM121
D7
THE IMPORTANCE OF MODEL CONCEPTUALISATION: A CASE STUDY IN ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)
Sideris E, Soares M, Palmer S
University of York, Heslington, York, UK

PRM122
D8
UNDERSTANDING THE POLICY-RELEVANT PORTION OF THE EFFICIENT FRONTIER IN SCREENING INTERVENTIONS: THE IMPORTANCE OF COMPARATOR STRATEGIES
O'Mahony JF
Trinity College Dublin, Dublin, Ireland

PRM123
D9
INVESTIGATING THE IMPLEMENTATION OF ADVERSE EVENTS IN ECONOMIC MODELS: A SYSTEMATIC LITERATURE REVIEW IN MULTIPLE SCLEROSIS AND HUMAN IMMUNODEFICIENCY VIRUS
Gillies H1, Polyzoi M2, Medin E2
1PAREXEL International, London, UK, 2PAREXEL International, Stockholm, Sweden

PRM124
D10
MAPPING THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE MEASURE (IBS-QOL) TO EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA (IBS-D)
Bjorner JB1, Rendas-Baum R2, Carson RT3, Boer R4, Tucker C5, Andrae DA6, Brazier JE7
1Optum Outcomes, Lincoln, RI, USA, 2Optum, Lincoln, RI, USA, 3Allergan plc, Jersey City, NJ, USA, 4Allergan plc, Irvine, CA, USA, 5Allergan plc, Marlow, Buckinghamshire, UK, 6Allergan plc, Austin, TX, USA, 7University of Sheffield, Sheffield, UK

PRM125
D11
INFLUENCE OF AIR POLLUTION ON SOME PREGNANCY OUTCOMES AND BURDEN OF PNEUMONIA ON CHILDREN UNDER FIVE YEARS OLD IN MONGOLIA
Dorj G, Dorj G, Gendenragchaa B, Ochir C
Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

PRM126
D12
DEFINING REAL-WORLD PRODUCT PERFORMANCE USING SURVIVAL ANALYSIS AND SUPERIVSED MACHINE LEARNING
Geldof T1, van Dyck W2, Moreau Y1
1KU Leuven, Leuven, Belgium, 2Vlerick Business School, Brussels, Belgium

PRM127
D13
COMPARISON STUDY BASED ON SIMULATION OF PATIENT PATHWAYS USING MULTI-STATE MODELS IN ONCOLOGY
Rakonczai P, Lang Z, Balazs T, Bacskai M
Healthware Consulting Ltd., Budapest, Hungary

PRM128
D14
PHARMACOLOGICAL INTERVENTIONS FOR FAMILIAL HYPERCHOLESTEROLAEMIA IN CHILDREN AND ADOLESCENTS: AN EXPLORATORY EVALUATION USING ADVANCED HIERARCHICAL NETWORK META-ANALYSIS TECHNIQUES
Langford BE, Wickstead RM, Murphy D, Marsh W, Beale RC, Evans JS, Kusel J, Griffiths M
Costello Medical Consulting Ltd, Cambridge, UK

PRM129
D15
INVESTIGATING THE EFFECTS OF TESTING AND ADJUSTING FOR NONLINEARITY USING CATEGORIZATION IN PREDICTION MODELS WITH COSTS AS OUTCOME
Brouwers DB, Nieboer D, Bosmans JE, van Tulder MW, Heymans MW, van Dongen JM
Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

PRM130
D16
COMPARATIVE EFFICACY OF TIME TO VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE HIV-1 PATIENTS: A NETWORK META-ANALYSIS OF LONGITUDINAL DATA
Snedecor SJ
Pharmerit International, Bethesda, MD, USA

PRM131
D17
METHODOLOGICAL REVIEW OF SURVIVAL MODELS: APPLICATION TO A PERSISTENCE ANALYSIS BASED ON LONG ACTING PARENTERAL ANTIPSYCHOTIC IN RETAIL PHARMACIES IN FRANCE
Harmand S, El Mouaddin N
IMS Health, Puteaux, France

PRM132
D18
PREDICTING PATIENT-REPORTED OUTCOMES FROM DISEASE-SPECIFIC QUESTIONNAIRES: A COMPARISON OF SEVEN METHODOLOGIES
Gheorghe M
Erasmus University, Rotterdam, The Netherlands

PRM133
D19
GENERALISING RESULTS FROM COST-EFFECTIVENESS ANALYSIS: A COMPARISON OF METHODS TO ACCOUNT FOR COVARIATES
Mantopoulos T1, Dias S1, Welton NJ2
1University of Bristol, BRISTOL, UK, 2University of Bristol, Bristol, UK

PRM134
D20
STATISTICAL MODELS TO PREDICT INDICATION OF RESPIRATORY PATIENTS BETWEEN ASTHMA AND COPD
Ilgin Y1, Staus A1, Chauvin F2, Leheyda N1, Wolk A1, Witte M3, Subramani S2
1IMS Health, Frankfurt, Germany, 2IMS Health, La Defense Cedex, France, 3IMS Health, London, UK

PRM135
D21
BRAIN METASTASIS PREDICTION IN BREAST CANCER WOMEN: USEFULNESS OF MATHEMATICAL MODELING OF MONTECARLO
Sat-Muñoz D1, Balderas-Peña L2, Cruz-Corona E2, Ortiz-González F3, Chagollán-Ramírez J4, Chávez-Hurtado J5
1Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 2UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, 3Unidad Médica de Alta Especialidad Hospital de Especialidades. Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico, 4Universidad de Guadalajara. Centro Universitario de Ciencias Económico Administrativas, Zapopan, Jalisco, Mexico, 5Universidad de Guadalajara, Zapopan, Mexico

PRM136
D22
REFLECTING UNCERTAINTY IN EARLY HTA WHEN EVIDENCE ON PARAMETER DISTRIBUTIONS IS LACKING: A COMPARISON OF METHODS
Koffijberg H1, Degeling K1, Janssen MP2, IJzerman MJ1
1University of Twente, Enschede, The Netherlands, 2University Medical Center Utrecht, Utrecht, The Netherlands

PRM137
D23
LENALIDOMIDE FOR TREATING MULTIPLE MYELOMA AFTER 1 PRIOR TREATMENT; AN APPLICATION OF MULTI-STATE MARKOV MODELLING FOR THE EXTRAPOLATION OF PATIENT LEVEL SURVIVAL DATA
Saunders O1, Gregory J1, Lee D1, Farrell J2
1BresMed, Sheffield, UK, 2Celgene, Uxbridge, UK

PRM138
D24
BOOSTING A MODELLER'S ARMOURY: PURSUING REALISTIC AND EFFICIENT COMPETING RISK HEALTH ECONOMIC MODELS (HEMS)
Kay SW
Model Outcomes Ltd, Cheshire, UK

PRM139
D25
METHODS FOR TIME-VARYING EXPOSURE – A LITERATURE REVIEW
Linder M1, Vago E2, Bahmanyar S1, Heeg B3, Myers D4, Zhang M5, Andersen M1
1Karolinska Institutet, Stockholm, Sweden, 2Jansen, Budapest, Hungary, 3Ingress Health, Rotterdam, The Netherlands, 4Jansen, Stockholm, Sweden, 5Jansen Scientific Affairs, Titusville, NJ, USA

PRM140
D26
CORRECTLY CAPTURING UNCERTAINTY IN TREATMENT EFFECTS IN SIMULATION MODELING
Willis M, Asseburg C
The Swedish Institute for Health Economics (IHE), Lund, Sweden

PRM141
D27
DEVELOPING A CONCEPTUAL FRAMEWORK AND A TOOL FOR MEASURING ABSORPTIVE CAPACITY IN PHARMACEUTICAL COMPANIES
Sanati E1, Kebriaeezadeh A2, Davari M3, Abdollahi asl A2, Keshavarz K4
1Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of), 2Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Shiraz University of Medical Sciences, School of Management and Information Sciences, Shiraz, Iran (Islamic Republic of)

PRM142
D28
KEY ASPECTS IN THE MODELLING OF DENGUE TRANSMISSION: RESULTS FROM A FOCUSED LITERATURE REVIEW
Kharitonova E1, Aballea S1, Knerer G2
1Creativ-Ceutical, Paris, France, 2Takeda Pharmaceuticals International GmbH, Zurich, Switzerland

RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM143
D29
QUALITY OF LIFE OF PATIENTS TREATED FOR MULTIPLE MYELOMA (MM) IN FRANCE IN A REAL-WORLD SETTING
Despiegel N1, Touboul C2, Flinois A2, Saba G2, Gonzalez-McQuire S3, Suzan F3, Blachier-Poisson C1, Guilhaume C1
1Amgen France, Paris, France, 2Kantar Health, Paris, France, 3Amgen (Europe) GmbH, Zug, Switzerland

PRM144
D30
WITHDRAWN

PRM145
D31
USING ACOUSTIC SIMULATIONS OF HEARING LOSS TO DESCRIBE HEALTH STATES: ARE THEY FEASIBLE AND RELIABLE TO USE?
Williams NJ1, Pierzycki R1, Akeroyd MA2, Kitterick PT1
1NIHR Nottingham Hearing Biomedical Research Unit, Nottingham, UK, 2MRC Institute of Hearing Research, Nottingham, UK

PRM146
D32
FURTHER VALIDATION OF THE HAEMOPREF IN A REAL-WORLD SETTING
Tolley C1, Staunton H1, Brohan E1, Spurden D2, Cicchetti M3, Cappelleri JC4
1Adelphi Values Ltd, Bollington, UK, 2Pfizer Limited, Surrey, UK, 3ExecuPharm Inc (On assignment as Protocol Operations Lead), Collegeville, PA, USA, 4Pfizer, Inc, Groton, CT, USA

PRM147
D33
AN INTERNATIONAL PATIENT SURVEY ON HEALTH RELATED QUALITY OF LIFE ASPECTS NOT CPATURED BY EQ-5D-5L
Mossman J1, Efthymiadou O2, Kanavos P2
1European Brain Council, Brusells, Belgium, 2London School of Economics and Political Science, London, UK

PRM148
D34
EXTERNAL VALIDITY AT STAKE IN MAPPING NON-PREFERENCE BASED DISEASE SPECIFIC MEASURES TO GENERIC PREFERENCE-BASED UTILITY VALUES IN ADVANCED CUTANEOUS MELANOMA
Franken M1, Leeneman B1, Jochems A2, Schouwenburg M2, Aarts M3, van Akkooi A4, van den Berkmortel F5, van den Eertwegh A6, Groenewegen G7, de Groot J8, Haanen J4, Hospers G9, Kapiteijn H10, Koornstra R11, Kruit W12, Louwman M13, Piersma D14, van Rijn R15, ten Tije A16, Vreugdenhil G17, Wouters M4, van Zeijl M2, van der Hoeven J1, Uyl-de Groot C18
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Dutch Institute for Clinical Auditing, Leiden, The Netherlands, 3Maastricht University Medical Center, Maastricht, The Netherlands, 4Netherlands Cancer Institute, Amsterdam, The Netherlands, 5Zuyderland Hospital, Heerlen, The Netherlands, 6VU University Medical Center, Amsterdam, The Netherlands, 7University Medical Center Utrecht, Utrecht, The Netherlands, 8Isala Hospital, Zwolle, The Netherlands, 9University Medical Center Groningen, Groningen, The Netherlands, 10Leiden University Medical Center, Leiden, The Netherlands, 11Radboud University Medical Center, Nijmegen, The Netherlands, 12Erasmus Medical Center, Rotterdam, The Netherlands, 13Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 14Medical Spectrum Twente, Enschede, The Netherlands, 15Medical Center Leeuwarden, Leeuwarden, The Netherlands, 16Amphia Hospital, Breda, The Netherlands, 17Maxima Medical Center, Eindhoven, The Netherlands, 18Erasmus University, Rotterdam, The Netherlands

PRM149
D35
MEASURING CAREGIVER QUALITY OF LIFE; WHICH ASPECTS REALLY MATTER?
Efthymiadou O
London School of Economics and Political Science, London, UK

PRM150
D36
VALUATION OF EQ-5D-5L HEALTH STATES: A COMPARISON OF THREE ASIAN COUNTRIES
Luo N1, Wang P1, Liu G2, Juntana P3
1National University of Singpaore, Singapore, Singapore, 2Peking University, Beijing, China, 3Social and Administrative Pharmacy Excellence Research Unit (SAPER Unit), Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

PRM151
D37
A NEW APPROACH TO PRESENTING HEALTH STATES IN STATED PREFERENCE VALUATION STUDIES
Cole AM1, Shah K1, Mulhern B2, Feng Y1, Devlin N1
1Office of Health Economics, London, UK, 2University of Technology Sydney, Sydney, Australia

PRM152
D38
THE QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) IN (IMMUNO)-ONCOLOGY: A SYSTEMATIC REVIEW OF THE LITERATURE
Wan Y, Tai M, Botteman M
Pharmerit International, Bethesda, MD, USA

PRM153
E1
DEVELOPMENT OF A MAPPING ALGORITHM BETWEEN THE SGRQ AND EQ-5D-5L UTILITY VALUES IN A SEVERE ASTHMA POPULATION
Willson J1, Mukuria CW2, Labeit A2, Gunsoy N3, Starkie Camejo H4, Alfonso-Cristancho R5, Brazier J2
1GSK, Middlesex, UK, 2University of Sheffield, Sheffield, UK, 3GSK, Stockley Park, Uxbridge, Middlesex, UK, 4GSK, Uxbridge, UK, 5GSK, Collegeville, PA, USA

PRM154
E2
PSYCHOMETRIC VALIDATION OF THE PULMONARY ARTERIAL HYPERTENSION SYMPTOMS AND IMPACT (PAH-SYMPACT®) QUESTIONNAIRE
Gomberg-Maitland M1, Channick R2, Chin K3, Fischer A4, Frantz R5, Roberts L6, Miller C7, Hunsche E8, Zamanian R9, Zastrow M10, Badesch D4
1University of Chicago, Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3University of Texas Southwestern, Dallas, TX, USA, 4University of Colorado Denver, Aurora, CO, USA, 5Mayo Clinic Rochester, Rochester, MN, USA, 6Evidera, Bethesda, MD, USA, 7Piedmont Healthcare, Atlanta, GA, USA, 8Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 9Stanford University, Stanford, CA, USA, 10Actelion Pharmaceuticals US Inc, South San Francisco, CA, USA

PRM155
E3
AN ANCHOR-BASED APPROACH TO DEFINE AN IMPAIRED DAY IN MIGRAINE PATIENTS UTILIZING THE MIGRAINE PHYSICAL FUNCTION IMPACT DIARY
Kawata AK1, Sapra S2, Desai PR2, Ortmeier BG2, Gleeson S1, Revicki DA1, Lipton RB3, Bayliss M4, Hareendran A5
1Evidera, Bethesda, MD, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3Albert Einstein College of Medicine, Bronx, NY, USA, 4Optum, Lincoln, RI, USA, 5Evidera, London, UK

PRM156
E4
TO TREAT OR WATCH? IDENTIFYING DRIVERS OF DECISIONS FOR PATIENTS WITH GEP-NET USING REFLECTIVE MULTI-CRITERIA DECISION ANALYSIS
Goetghebeur MM1, Samaha D2, Khoury H2, O'Neil B2, Lavoie L2, Bennetts L2, Wagner M2, Badgley D2, Gabriel S3, Berthon A4, Dolan J5, Kulke M6
1LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3IPSEN Pharma, Boulogne-Billancourt, France, 4IPSEN, Boulogne-Billancourt, France, 5University of Rochester, Rochester, NY, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA

PRM157
E5
DEVELOPMENT AND CONTENT VALIDITY OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF)
Mazar I1, Evans E2, Taylor F1, Patki A2, Ojo O1, Lamoureux RE1, Horny H3, Reiter A4, Gotlib J5, Shields A1
1Adelphi Values, Boston, MA, USA, 2Blueprint Medicines, Cambridge, MA, USA, 3Ludwig-Maximilians University, München, Germany, 4Universitätsmedizin Mannheim, Mannheim, Germany, 5Stanford University, Standord, CA, USA

PRM158
E6
CONCEPTUAL MODEL AND CLINICAL OUTCOMES ASSESSMENTS FOR ANGELMAN’S SYNDROME: UTILIZING PRAGMATIC METHODS IN RARE DISEASES
Abetz-Webb L1, Cabo R2, Grieco J2, Rakhit A2, During M2
1Patient-Centred Outcomes Assessments, Bollington, UK, 2Ovid Therapeutics, New York, NY, USA

PRM159
E7
ANALYZING A GERMAN INDEX FOR THE EQ-5D-5L BASED ON EXPERIENCED HEALTH
Leidl R, Reitmeir P
Helmholtz Zentrum Munchen, Neuherberg, Germany

PRM160
E8
THE IMPACT OF COUNTRY-SPECIFIC UTILITY TARIFFS ON THE OUTCOME OF COST-UTILITY ANALYSES; A CASE STUDY
Bosmans JE, Rossenaar MM, van Dongen JM, van Tulder MW
Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

PRM161
E9
USING ORTHOGONAL DESIGN IN SELECTING HEALTH STATES FOR THE CONSTRUCTION OF EQ-5D-3L VALUE SET
Yang Z1, Luo N2, van Busschbach J3, Stolk E4
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2National University Singapore, Singapore, Singapore, 3Erasmus MC, Rotterdam, The Netherlands, 4EuroQol Research Foundation, Rotterdam, The Netherlands

PRM162
E10
ELICITING STATED PREFERENCES REGARDING LIFE EXTENSIONS NEAR THE END OF LIFE: A PILOT STUDY FOR A REFINEMENT OF THE QALY
Taylor M1, Filby A2, Elvidge JS3
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium, Heslington, York, UK, 3University of Manchester, Manchester, UK

PRM163
E11
HEALTH-RELATED QUALITY OF LIFE IN OPIOID USE DISORDER MEASURED BY UTILITIES: A SYSTEMATIC LITERATURE REVIEW
Cranmer H1, Ronquest NA2, Barnes A1, Nadipelli VR2, Akehurst R1
1BresMed Health Solutions, Sheffield, UK, 2Indivior Inc., Richmond, VA, USA

PRM164
E12
RECONSIDERING EQ-5D; QUALITY OF LIFE DOMAINS THAT ARE IMPORTANT FOR MULTIPLE SCLEROSIS PATIENTS
Mossman J, Efthymiadou O, Tinelli M, Kanavos P
London School of Economics and Political Science, London, UK

PRM165
E13
"WHY CAN'T I JUST USE GOOGLE TRANSLATE?" A STUDY ON THE EFFECTIVENESS OF ONLINE TRANSLATION TOOLS IN TRANSLATION OF COAS
Lear A1, Oke L2, Forsythe C2, Richards A2
1ICON PLC, Abingdon, UK, 2ICON Plc, Abingdon, UK

PRM166
E14
WHAT MATTERS MOST? AN EXPLORATION OF DECISION CRITERIA CONSIDERED BY PATIENTS WITH GEP-NET AND PHYSICIANS USING HOLISTIC MULTI-CRITERIA DECISION ANALYSIS
Goetghebeur MM1, Samaha D2, O'Neil B2, Khoury H2, Bennetts L2, Lavoie L2, Wagner M2, Badgley D2, Gabriel S3, Berthon A4, Dolan J5, Kulke M6
1LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3IPSEN Pharma, Boulogne-Billancourt, France, 4IPSEN, Boulogne-Billancourt, France, 5University of Rochester, Rochester, NY, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA

PRM167
E15
A SYSTEMATIC REVIEW OF UTILITY DERIVATION METHODS: TIME TRADE OFF IN COMPARISON TO EQ-5D
Vollmer L1, Shannon RJ2, Walzer S2
1Geographic Solutions in Health, Tuebingen, Germany, 2MArS-imulation UG (h.b.), Weil am Rhein, Germany

PRM168
E16
QUALITATIVE RESEARCH APPROACHES IN RARE DISEASES: ACID SPHINGOMYELINASE DEFICIENCY (ASMD) SYMPTOMS AND IMPACT AS REPORTED BY PATIENTS AND CAREGIVERS
Avetisyan R1, Hareendran A2, Stringer S3, Tan S1, Sanson B1, Hass S1
1Sanofi Genzyme, Cambridge, MA, USA, 2Evidera, London, UK, 3Evidera, Bethesda, MD, USA

PRM169
E17
FORE! SWEEPING GENERALISATIONS DO NOT BOWL OVER ALL CULTURES… CULTURAL ADAPTATION IN THE KIDNEY DISEASE QUALITY OF LIFE QUESTIONNAIRE
Richards A, Mead H, Towns L
ICON Plc, Abingdon, UK

PRM170
E18
SYSTEMATIC REVIEW OF PSYCHOMETRIC PROPERTIES OF THE EQ-5D QUESTIONNAIRES IN PATIENTS WITH HEMATOLOGIC MALIGNANT NEOPLASMS
Mlynczak K1, Wojcik A1, Golicki D2
1HealthQuest, Warsaw, Poland, 2Department of Experimental & Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

PRM171
E19
CONTENT VALIDATION OF THE PULMONARY ARTERIAL HYPERTENSION SYMPTOMS AND IMPACT (PAH-SYMPACT®) QUESTIONNAIRE
Gomberg-Maitland M1, Channick R2, Chin K3, Fischer A4, Frantz R5, Roberts L6, Miller C7, Hunsche E8, Zamanian R9, Badesch D4
1University of Chicago, Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3University of Texas Southwestern, Dallas, TX, USA, 4University of Colorado Denver, Aurora, CO, USA, 5Mayo Clinic Rochester, Rochester, MN, USA, 6Evidera, Bethesda, MD, USA, 7Piedmont Healthcare, Atlanta, GA, USA, 8Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 9Stanford University, Stanford, CA, USA

PRM172
E20
A STUDY OF THE SUCCESSFUL ADAPTATION OF THE QUALITY OF LIFE QUESTIONNAIRE - BRONCHIECTASIS FROM PAPER TO ELECTRONIC FORMAT
Simpson H1, Ong SH2, Quittner A3, McEvoy K4, Dhariwal M5
1Corporate Translations, Inc., East Hartford, CT, USA, 2Novartis Pharma AG, Basel, Switzerland, 3University of Miami, Miami, FL, USA, 4CRF Health, London, UK, 5Novartis Ireland Ltd, Dublin, Ireland

PRM173
E21
COMPARING THE EQ-5D-5L VALUE SETS ACROSS DIFERENT COUNTRIES – IMPACT ON INPERTRETATION OF CLINICAL STUDY RESULTS
Gerlinger C1, Bamber L2, Leverkus F3, Schwenke C4, Haberland C1, Schmidt G5, Endrikat J1
1Bayer Pharma AG, Berlin, Germany, 2Bayer Pharma AG, Wuppertal, Germany, 3Pfizer Deutschland GmbH, Berlin, Germany, 4SCO:SSiS, Berlin, Germany, 5Saarland University, Homburg/Saar, Germany

PRM174
E22
TRANSLATABILITY EVALUATION OF THE ROME IV DIAGNOSTIC QUESTIONNAIRE FOR ADULTS
Crane AL1, Campbell T1, Popielnicki A2, Sperber AD3, Drossman D4, Palsson OS5, Whitehead WE5, Sweeney E1, O'Brien K1
1TransPerfect, New York, NY, USA, 2TransPerfect, Boston, MA, USA, 3Ben-Gurion University of the Negev, Beer-Sheva, Israel, 42University of North Carolina, Chapel-Hill, NC, USA, 5University of North Carolina, Chapel Hill, NC, USA

PRM175
E23
UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA
Hadi M1, Swinburn P1, de Freitas HM1, Ito T2
1Mapi Group, London, UK, 2Janssen Health Economics & Market Access EMEA, High Wycombe, UK

PRM176
E24
WELL-BEING: WHAT IS IT, HOW DOES IT COMPARE TO HEALTH AND WHAT ARE THE IMPLICATIONS OF USING IT TO INFORM HEALTH POLICY?
Brazier J1, Mukuria CW1, Peasgood T1, Bjorner JB2
1University of Sheffield, Sheffield, UK, 2Optum, Lincoln, RI, USA

PRM177
E25
CROSS-CULTURAL ADAPTATION OF THE ZARIT CAREGIVER INTERVIEW FOR ALZHEIMER'S DISEASE (ZCI-AD) AND THE CAREGIVER GLOBAL IMPRESSION SCALES IN 13 LANGUAGES
Le Scouiller S1, Edgar C1, Rylands A1, Giroudet C2, Regnault A3, Zarit S4, Rofail D1
1Roche Products Limited, Welwyn Garden City, UK, 2Mapi, Lyon, France, 3Modus Outcomes, Lyon, France, 4Pennsylvania State University, University Park, PA, USA

PRM178
E26
USING ANALYTIC HIERARCHY PROCESS TO WEIGHT PATIENT-RELEVANT OUTCOMES IN THE TREATMENT OF PSORIASIS FOR CALCULATING THE PATIENT BENEFIT INDEX
Gutknecht M1, Danner M2, Augustin M1
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2University Hospital Cologne, Cologne, Germany

PRM179
E27
TRANSLATION OF THE DN4 (DOULEUR NEUROPATHIQUE EN 4 QUESTIONS) INTO 85 LANGUAGES: CHALLENGES AND IMPORTANCE OF THE CONCEPTUAL DEFINTION OF THE ORIGINAL VERSION
Bouhassira D1, Dulac M2, Bindi P2, Nguyen A3, Acquadro C2
1Ambroise Paré Hospital, Boulogne-Billancourt, France, 2Mapi Research Trust, Lyon, France, 3Mapi, Lyon, France

PRM180
E28
MULTIPLE MYELOMA AND HEALTH-RELATED QUALITY OF LIFE FROM EQ-5D AND EORTC: A SYSTEMATIC LITERATURE REVIEW
Qerimi V1, Jahn B2, Vukicevic D3, Jevdjevic M3, Holzner B4, Kemmler G4, Siebert U5, Rochau U6
1UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Skopje, Macedonia, Hall i.T., Austria, 2Department of Public Health, Health Services Research and Health Technology Assessment, Medical Informatics and Technology (UMIT), Hall i.T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, 4Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, Innsbruck, Austria, 5and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria, 6UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment, Hall i.T./Innsbruck, Austria

PRM181
E29
TRANSLATION OF CHINESE VERSION OF MEASURE YOURSELF MEDICAL OUTCOME PROFILE (MYMOP) AND APPLICATION IN THE CORONARY HEART DISEASE
Zhang F1, Zhang S2, Wang Y1, Zhang Z1, Yang G2
1The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Liaoning, China, Shenyang, China, 2Liaoning University of Traditional Chinese Medicine, Liaoning, China, Shenyang, China

PRM182
E30
EUROQOL TO ASSESS THE QUALITY OF LIFE WITH SMARTPHONE
Vorobiev A1, Vorobiev P1, Krasnova L1, Vorobiev M2
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russian Federation, 2Newdiamed, Moscow, Russian Federation

PRM183
E31
PERFORMANCE OF SEARCH FILTERS TO IDENTIFY HEALTH STATE UTILITY STUDIES
Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville J
York Health Economics Consortium, York, UK

PRM184
E32
WHEN SHOULD TRANSLATIONS OF CLINICAL OUTCOME ASSESSMENTS (COAS) BE CONSIDERED OBSOLETE? RECOMMENDATIONS FROM MAPI’S TRANSLATIONS LIFE EXPECTANCY WORKING GROUP
Giroudet C1, Salmassi L1, Prill M1, Berne C2, Berrou M1, Boudrot A1
1Mapi, Lyon, France, 2Mapi Research Trust, Lyon, France

PRM185
E33
RECOMMENDATIONS ON COGNITIVE DEBRIEF AND USABILITY STUDIES FOR INSTRUMENT MIGRATION FROM PAPER TO ELECTRONIC MODALITIES BASED ON A QUALITATIVE SYNTHESIS OF VALIDATION STUDIES
Muehlhausen W1, Byrom B2, Skerritt B3
1ICON plc, Dublin 18, Ireland, 2ICON Clinical Research, Marlow, UK, 3ICON, Dublin, Ireland

PRM186
E34
LINGUISTIC VALIDATION AND ELECTRONIC MIGRATION OF THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE (KCCQ)
Sydor B1, Spertus J2
1TransPerfect, Washington, DC, USA, 2Health Outcomes Sciences, Overland Park, KS, USA

PRM187
E35
LINGUISTIC VALIDATION OF THE INJECTION-TREATMENT ACCEPTANCE QUESTIONNAIRE (I-TAQ)
Crane AL1, Popielnicki A2, Sanchez RJ3
1TransPerfect, New York, NY, USA, 2TransPerfect, Boston, MA, USA, 3PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PRM188
E36
DEVELOPMENT OF A GUIDANCE ON THE IMPLEMENTATION AND USE OF EORTC INSTRUMENTS IN ELECTRONIC APPLICATIONS
Kulis D1, Bottomley A1, Holzner B2, Koller M3, Swinburn P4, Itani A5
1EORTC, Brussels, Belgium, 2Medical University of Innsbruck, Innsbruck, Austria, 3University Hospital Regensburg, Regensburg, Germany, 4Mapi Group, London, UK, 5Mapi, Lyon, France

PRM189
E37
VIEWPOINTS OF THALASSAEMIA PATIENTS ON THE COMBINATION OF TRADITIONAL & COMPLEMENTARY MEDICINE (T&CM) WITH THE CONVENTIONAL THALASSAEMIA TREATMENT:A QUALITATIVE UNDERSTANDING APPROACH
Ismail wI1, Hassali MA2, Farooqui M3, Saleem F4
1Faculty of Health Sciences University Technology MARA, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3Qassim University, Qassim, Saudi Arabia, 4University of Bolochistan, Quetta, Pakistan

PRM190
E38
INCORPORATING BIOMETRIC DATA FROM WEARABLE ACTIVITY TRACKERS WITH STUDY DATA IN FRANCE AND THE UK
Fink L1, Chanot G1, Bernard F1, Mondry B2, Normand A3, Vegreville M3, Bondarenko K1
1Kantar Health, Paris, France, 2Kantar Health, New York, NY, USA, 3Withings, Issy-les-Moulineaux, France

PRM191
F1
WATCH OUT FOR BERKSON'S BIAS (BB)! SETTING HEALTH-RELATED QUALITY OF LIFE (HRQOL) TREATMENT TARGETS WITH MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) IN ORDER TO PREDICT MATCHED GENERAL POPULATION CONTROL (MGPC) TARGETS, ASSESS POTENTIAL TO BENEFIT (PTB) AND REVEAL UNMET MEDICAL NEED (UMN)
Soini EJ1, Heinonen J2, Miettola E2, Ryynänen O3, Koskela T4
1ESIOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland, 3Faculty of Health Sciences, University of Eastern Finland, and Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4Department of General Practice, University of Tampere, and Omapihlaja, Pihlajalinna Terveys Oy, Tampere, Finland

PRM192
F2
WHAT CRITERIA INFLUENCE TREATMENT DECISION-MAKING IN ELDERLY COLORECTAL CANCER PATIENTS?
Keizer J1, IJzerman MJ1, van Til JA1, Wymenga AM2
1University of Twente, Enschede, The Netherlands, 2Medical Spectrum Twente Hospital, Enschede, The Netherlands

PRM193
F3
THE ECONOMIC IMPACT OF INFLUENZA-LIKE ILLNESS ON FAMILIES LIVING IN THE UK DEMONSTRATED BY THE COLLECTION OF ONLINE DATA
Wade AG, Crawford GM, McLennan K
Patients Direct, Glasgow, UK

RESEARCH ON METHODS - Statistical Methods
PRM194
F4
COMPARISON OF METHODS FOR INDIRECT TREATMENT COMPARISON COMBINING INDIVIDUAL AND AGGREGATE PATIENT DATA: A SIMULATION
Rasouliyan L
RTI Health Solutions, Barcelona, Spain

PRM195
F5
THE ADDED VALUE OF REAL-WORLD EVIDENCE TO CONNECT DISCONNECTED NETWORKS FOR NETWORK META-ANALYSIS: A CASE STUDY IN RHEUMATOID ARTHRITIS
Jenkins DA, Martina R, Dequen P, Bujkiewicz S, Abrams K
University of Leicester, Leicester, UK

PRM196
F6
COMPARISON OF BAYESIAN NETWORK META-ANALYSES IN A WINBUGS AND SAS FRAMEWORK
Le Moine J, Abeysinghe SS
RTI Health Solutions, Didsbury, UK

PRM197
F7
ADJUSTING VARIANCE PARAMETERS TO INCORPORATE UNCERTAINTY INTO HEALTH ECONOMICS MODELS FOLLOWING TREATMENT SWITCHING
Ray J1, Bennett I2, Paracha N2
1F. Hoffmann-La Roche, Basel, Switzerland, 2F. Hoffman-La Roche, Basel, Switzerland

PRM198
F8
EXTRACTING DOSAGE PER DAY FROM FREE-TEXT MEDICATION PRESCRIPTIONS
Törnblom M1, Bergman G2, Jørgensen L3, Fackle-Fornius E1, Rosenlund M2
1Stockholm University, Stockholm, Sweden, 2IMS Health, Solna, Sweden, 3Pygargus/IMS Health, Solna, Sweden

PRM199
F9
IDENTIFYING HIGHER-VALUE SUBPOPULATIONS FOR TREATMENT IN HETEROGENOUS RARE DISEASES: AN EXAMPLE STUDY OF EARLY RESPONDERS TO TEDUGLUTIDE FOR SHORT BOWEL SYNDROME
Chen K1, Xie J2, Tang C2, Zhao J3, Olivier C4, Jeppesen PB5, Signorovitch J3
1Shire plc, Lexington, MA, USA, 2Analysis Group, New York, NY, USA, 3Analysis Group, Boston, MA, USA, 4Shire GmbH, Zug, Switzerland, 5Rigshospitalet, Copenhagen, Denmark

PRM200
F10
IS EARLY INITIATION OF BIOLOGIC TREATMENT MORE EFFECTIVE THAN A STEP UP TREATMENT APPROACH FOR NEW ONSET JUVENILE IDIOPATHIC ARTHRITIS?-- USING A CAUSAL INFERENCE APPROACH TO ACHIEVE A DOUBLE ROBUST ESTIMATE
Huang B1, Morgan E1, Chen C1, Adams M1, Brunner H1, Guo J2, Seid M1
1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, 2Univeristy of Cincinnati, Cincinnati, OH, USA

PRM201
F11
ADJUSTMENT OF OS IN CRYSTAL FOR POST-STUDY ANTI-CANCER THERAPIES
Stapelkamp C1, Byrne B1, van Hout B2
1Merck Serono Ltd., Feltham, UK, 2University of Sheffield, Sheffield, UK

PRM202
F12
NETWORK META-ANALYSIS ACROSS LONGITUDINAL TIME POINTS: A COMPARISON OF AVAILABLE METHODS
Tallarita M1, de Iorio M1, Baio G1, Karabis A2
1University College London, London, UK, 2Mapi Group, Houten, The Netherlands

PRM203
F13
THE USE OF ‘OFF THE SHELF’ INFORMATIVE PRIOR DISTRIBUTIONS IN RANDOM EFFECT NETWORK META-ANALYSIS MODELS
Batson S1, Abrams K2, Sutton A2
1DRG, Bicester, UK, 2University of Leicester, Leicester, UK

PRM204
F14
RECREATIONAL USE OF PHOSPHODIESTERASE 5 INHIBITORS AND ITS ASSOCIATED FACTORS AMONG UNDERGRADUATE MALE STUDENTS IN AN ETHIOPIAN UNIVERSITY: A CROSS-SECTIONAL STUDY
Gebreyohannes EA1, Bhagavathula AS1, Gebresillassie bM2, Tefera YG1, Belachew SA2, Erku dA2
1University of Gondar, Gondar, Ethiopia, 2university of gondar, gondar, Ethiopia

RESEARCH ON METHODS - Study Design
PRM205
F15
A SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY-EFFECTIVENESS GAP: COMPARISON OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES OF GLUCOSE-LOWERING DRUGS
Ankarfeldt MZ1, Adalsteinsson E1, Groenwold RH2, Ali S3, Klungel O4
1Novo Nordisk A/S, Soeborg, Denmark, 2University Medical Center Utrecht, Utrecht, The Netherlands, 3University of Oxford, Oxford, UK, 4Utrecht University, Utrecht, The Netherlands

PRM206
F16
MAKING SENSE OF CLINICAL DATA REPORTED IN SECONDARY CONDITIONS: THE EPIDEMIOLOGY AND CLINICAL BURDEN OF HYPERGLYCAEMIA
Cadwell K, Pooley N, Olariu E, Jones G, Papageorgakopoulou C, Fox D
PHMR Ltd, London, UK

PRM207
F17
HOW TO MAXIMISE THE VALUE AND PAYERS’ ACCEPTANCE OF SINGLE ARM TRIAL DATA IN ONCOLOGY?
Hoyle C1, Wright J2, Ede J3, van Engen A4, Ryan J1
1AstraZeneca, Cambridge, UK, 2Quintiles, Reading, UK, 3AstraZeneca, Cambridgeshire, UK, 4Quintiles Advisory Services, Hoofddorp, The Netherlands

PRM208
F18
IMPORTANT METHODOLOGICAL CONSIDERATIONS AND STRATEGIES FOR RESOLUTION FOR MULTINATIONAL RETROSPECTIVE CHART REVIEW STUDIES
Bassel M
UBC: An Express Scripts Company, Dorval, QC, Canada

PRM209
F19
VALIDITY AND RELIABILITY OF THREE NEW INSTRUMENTS FOR PARENTS AND CHILDREN ASSESSING NUTRITION AND PHYSICAL ACTIVITY BEHAVIORS, ENVIRONMENT AND KNOWLEDGE IN CHILDHOOD AND ADOLESCENCE IN GREECE DURING THE ECONOMIC RECESSION: DATA FROM THE NATIONAL ACTION PLAN FOR PUBLIC HEALTH (MIS301205)
Carayanni V1, Vlachopapadopoulou E2, Psaltopoulou T3, Koutsouki D3, Bogdanis G3, Karachaliou F2, Manios Y4, Kapsali A5, Papadopoulou A2, Hantzakis A3, Michalakos S2
1Technological Educational Institute of Athens, Athens, Greece, 2Children's Hosp. P. & A. Kyriakou, Athens, Greece, 3Univ. of Athens, Athens, Greece, 4Harokopio Univ. of Athens, Athens, Greece, 5Ministry of Health, Αthens, Greece

PRM210
F20
ADAPTING TO THE CHALLENGE: HOW ARE INNOVATIVE STUDY DESIGNS BEING USED IN RARE DISEASES?
Berry LJ, Eddowes LA
Costello Medical Consulting Ltd, Cambridge, UK

PRM211
F21
MAKING PRAGMATIC TRIALS WORK
Zuidgeest MG1, Stolk P1, Oude Rengerink K1, Goetz IA2, Welsing PM1, Grobbee DE1
1University Medical Center Utrecht, Utrecht, The Netherlands, 2Eli Lilly and Company, Windlesham, Surrey, UK

RESEARCH ON METHODS - Conceptual Papers
PRM212
F22
GENERATING REAL WORLD EVIDENCE: GUIDANCE ON THE DESIGN AND CONDUCT OF RETROSPECTIVE CHART REVIEW STUDIES
Korol E, Osenenko KM, Kayaniyil S, McMullen S
ICON Commercialisation & Outcomes, Vancouver, BC, Canada

PRM213
F23
WITHDRAWN

PRM214
F24
QUASI-EXPERIMENTAL METHODS FOR REAL WORLD DATA
Menke JM
A. T. Still Research Institute, Mesa, AZ, USA

PRM215
F25
WHEN IS THE USE OF A SYSTEMATIC LITERATURE REVIEW APPROPRIATE? A COMPARISON OF SYSTEMATIC, RAPID, AND SCOPING REVIEWS AND THEIR APPLICATION TO THE HTA PROCESS
Pooley N, Olariu E, Floyd D
PHMR Ltd, London, UK

PRM216
F26
RATIONALE AND DESIGN OF A MULTI-CENTER SURVEY TO EVALUATE PRODUCTIVITY LOSSES AND INDIRECT COSTS AFTER CARDIOVASCULAR EVENTS IN EUROPE
Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Annemans L3
1IMS Health, Zaventem, Belgium, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Ghent University - Brussels University, Ghent, Belgium

PRM217
F27
INNOVATIVE APPROACH TO KEEPING EVIDENCE CURRENT AND GUIDELINES LIVING
Lewis SZ, Newton M
Doctor Evidence, Santa Monica, CA, USA

PRM218
F28
COMPARISON BETWEEN CANCER DRUGS ASSESSMENT IN PORTUGAL AND UNITED KINGDOM
Carmo S1, Ramos R2, Crespo N1
1ISCTE-IUL, Lisbon, Portugal, 2INFARMED, I.P., Lisbon, Portugal

PRM219
F29
APPLICATION OF QUALITY INDICATORS TO ENABLE ECONOMIC EVALUATION OF QUALITY IMPROVEMENTS – A BAYESIAN DECISION THEORETICAL AND VALUE OF INFORMATION ANALYTICAL FRAMEWORK
Vestergaard AS, Holger Ehlers L
Aalborg University, Aalborg, Denmark

PRM220
F30
METHODS FOR THE DESIGN AND CONDUCT OF MEDICAL RECORD REVIEWS IN ONCOLOGY
Wilke T1, Baeten S2, Solem CT3, Penrod JR4, Verleger K5, Lees M4, Manley Daumont M4
1INGRESS-Health HWM GmbH, Wismar, Germany, 2SiRM - Strategies in Regulated Markets B.V., Den Haag, The Netherlands, 3Pharmerit International, Bethesda, MD, USA, 4Bristol-Myers Squibb, Paris, France, 5Pharmerit International, Berlin, Germany

PRM221
F31
HEALTH ECONOMICS ANALYSIS PLANS: WHERE ARE WE NOW?
Thorn JC1, Ridyard CH2, Hughes D2, Wordsworth S3, Mihaylova B3, Noble S1, Hollingworth W1
1University of Bristol, Bristol, UK, 2Bangor University, Bangor, UK, 3University of Oxford, Oxford, UK

PRM222
F32
MULTI-CRITERIA DECISION ANALYSIS FROM THE COST-EFFECTIVENESS PERSPECTIVE: IS MCDA A COHERENT WAY TO ALLOCATE HEALTHCARE RESOURCES?
O'Mahony JF
Trinity College Dublin, Dublin, Ireland

PRM223
F33
SYSTEMATIC REVIEW TOOLBOX
Marshall C1, Sutton A2
1York Health Economics Consortium Ltd, York, UK, 2University of Sheffield, Sheffield, UK

PRM224
F34
A PATIENT LEVEL SIMULATION MODEL
Gharibnaseri Z1, Davari M1, Cheraghali A2, Eshghi P3, Ravanbod R4, Spendar R1
1Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 2Baghyatollah Medical Sciences University, Tehran, Iran (Islamic Republic of), 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Tarbiat Modares University, Tehran, Iran (Islamic Republic of)

PRM225
F35
INTERACTIVE HEALTH ECONOMIC MODELS CONFIGURED WITH GOOGLE ANALYTICS. DATA AND METRICS APPLICABLE FOR A HEALTHCARE RESEARCH
Topachevskyi O1, Siabro V2, Volovyk A2
1Digital Health Outcomes, Brussels, Belgium, 2Digital Health Outcomes, Kiev, Ukraine

PRM226
F36
A CONCEPTUAL APPROACH FOR INCLUDING PRODUCTIVITY LOSSES IN HEALTH ECONOMIC EVALUATIONS FROM A SOCIETAL VIEWPOINT
Müller M, Hofmann S
WifOR GmbH, Darmstadt, Germany

PRM227
F37
GUIDANCE ON SELECTING APPROPRIATE METHODS WHEN CONSIDERING ADJUSTING OVERALL SURVIVAL FOR TREATMENT SWITCH IN ONCOLOGY STUDIES
Watkins CL1, Latimer N2, Wang J3, Wright EJ4
1Clarostat Consulting Limited, Alderley Edge, UK, 2University of Sheffield, Sheffield, UK, 3Celgene International, Boudry, Switzerland, 4Roche, Basel, Switzerland

PRM228
F38
USING EVIDENCE REVIEWS TO DEVELOP FOCUSED SYSTEMATIC REVIEW QUESTIONS
Upton CM, Chadda S, Chapman R, Curry A
SIRIUS Market Access, London, UK

PRM229
G1
UTILISATION OF SURVIVAL OUTCOMES DATA TO FORECAST ECONOMIC IMPACT OF PRICING AND MARKET ACCESS SCENARIOS IN A MULTI-INDICATION PATIENT FLOW MODELS
Sogokon P1, Hunt M1, Kjeldgaard-Pedersen J2, Furneri G3, Chalmers M1
1CBPartners, London, UK, 2data2Impact, Copenhagen, Denmark, 3EBMA Consulting SRL, Melegnano, Italy

PRM230
G2
VALUE AND COST CONUNDRUM IN ADVANCED ONCOLOGY: INTEGRATION OF VALUE FRAMEWORKS INTO COST-EFFECTIVENESS ANALYES
Ambavane A1, Benedict A2, Lanitis T1, Kongnakorn T1
1Evidera, London, UK, 2Evidera, Budapest, Hungary

PRM231
G3
DESIGN AND OPERATIONAL CONSIDERATIONS FOR HYBRID RETROSPECTIVE-PROSPECTIVE STUDIES
Page MJ, Walke HL
Medpace, Cincinnati, OH, USA

PRM232
G4
HOW ASSESSMENT METHODS MAY AFFECT THE EFFICIENCY OF APPRAISAL PROCESS: A CRITICAL REVIEW
Giorgia Tedesco G, Francesco Faggiano F, Andellini M, Leo E, Losito G, Pietro Derrico P, Matteo Ritrovato M
Bambino Gesù Children's Hospital, Rome, Italy

PRM233
G5
METHODS FOR ANALYZING PATIENT-REPORTED OUTCOMES IN ONCOLOGY TRIALS
Williams P1, Fofana F1, de la Loge C1, Arnould B2
1Mapi Group, Patient-Centered Outcomes, Lyon, France, 2Mapi Group, Lyon, France

PRM234
G6
A SECURE SMARTPHONE APPLICATION FOR CLINICAL RESEARCH ON WOUND HEALING: NURSTRIAL
Allaert F
Medical evaluation Chair ESC Dijon, Dijon, France

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.